Hologic (Nasdaq: HOLX ) is expected to report Q2 earnings on May 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hologic's revenues will grow 35.8% and EPS will increase 3.0%.
The average estimate for revenue is $639.8 million. On the bottom line, the average EPS estimate is $0.34.
Last quarter, Hologic recorded revenue of $631.4 million. GAAP reported sales were 34% higher than the prior-year quarter's $472.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.38. GAAP EPS of $0.01 for Q1 were 88% lower than the prior-year quarter's $0.08 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 61.3%, 120 basis points worse than the prior-year quarter. Operating margin was 13.1%, 430 basis points worse than the prior-year quarter. Net margin was 0.5%, 390 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $2.62 billion. The average EPS estimate is $1.58.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 671 members out of 691 rating the stock outperform, and 20 members rating it underperform. Among 162 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 156 give Hologic a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.82.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.